ADMA Biologics Inc (NASDAQ:ADMA) Given Consensus Rating of “Hold” by Analysts

ADMA Biologics Inc (NASDAQ:ADMA) has been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $19.6667.

A number of research firms have recently weighed in on ADMA. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Canaccord Genuity Group dropped their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th.

Insider Buying and Selling

In other news, Director Jerrold B. Grossman acquired 12,500 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 3.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new position in ADMA Biologics during the first quarter valued at approximately $31,000. Bank of America Corp DE raised its position in ADMA Biologics by 107.5% during the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after purchasing an additional 2,071,338 shares in the last quarter. Amundi raised its position in ADMA Biologics by 62.9% during the first quarter. Amundi now owns 51,761 shares of the biotechnology company’s stock valued at $466,000 after purchasing an additional 19,985 shares in the last quarter. California State Teachers Retirement System raised its position in ADMA Biologics by 24.0% during the first quarter. California State Teachers Retirement System now owns 279,124 shares of the biotechnology company’s stock valued at $2,515,000 after purchasing an additional 53,988 shares in the last quarter. Finally, Royal Bank of Canada raised its position in ADMA Biologics by 448.8% during the first quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock valued at $8,373,000 after purchasing an additional 759,984 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 0.3%

NASDAQ ADMA opened at $8.75 on Friday. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $20.46. The company has a 50 day moving average of $8.93 and a 200-day moving average of $13.40. The company has a market cap of $2.03 billion, a price-to-earnings ratio of 12.86 and a beta of 0.72.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. During the same period in the previous year, the business earned $0.11 earnings per share. The firm’s quarterly revenue was down .3% on a year-over-year basis. On average, equities research analysts expect that ADMA Biologics will post 0.82 earnings per share for the current fiscal year.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: Multiple law firms announced or reminded investors about an active securities class action against ADMA Biologics, with an August 10, 2026 lead-plaintiff deadline. The complaints allege potential securities law violations tied to disclosures about revenues, internal controls, and alleged “channel stuffing” claims. Article: Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
• Negative Sentiment: Bleichmar Fonti & Auld said a class action was filed after ADMA’s shares previously dropped sharply following Culper Research channel-stuffing allegations, reinforcing concerns about possible accounting or sales-practices issues. Article: $ADMA Fraud Alert: ADMA Biologics Investors Sue for Recovery in Securities Fraud Class Action after 29% Stock Drop – Investors Notified to Contact BFA Law
• Neutral Sentiment: Several other firms, including Rosen, Schall, Gross Law Firm, Kahn Swick & Foti, Bragar Eagel & Squire, and others, issued similar notices encouraging affected shareholders to seek counsel, adding more noise around the stock but not changing the underlying business picture yet. Article: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.